Nexentis Technologies Inc. (NXTS) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Nexentis Technologies Inc. operates primarily through two segments: Biotechnology (via its wholly-owned subsidiary MitoCareX, acquired in October 2025) and Renewable Energy (via NITO Renewable Energy and joint ventures). The company recently exited its food technology segment (Save Foods Ltd.) via a share exchange transaction in March 2026, classifying it as discontinued operations. All share data reflects a 1-for-7 reverse stock split effective April 8, 2026.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (USD) |
|---|---|
| Revenue | $0 (Continuing Operations) |
| Net Loss (Continuing Ops) | $(18,584,000) |
| Net Loss (Total) | $(17,749,000) |
| Operating Loss | $(10,101,000) |
| Financing Expenses, Net | $(8,939,000) |
| Cash and Cash Equivalents | $7,623,000 |
| Working Capital | $7,599,000 |
| Total Liabilities | $16,910,000 |
| Stockholders' Equity | $1,782,000 |
Note: The total net loss includes a net gain of $835,000 from discontinued operations (sale of Save Foods).
Material Changes vs. Prior Period
- Goodwill Impairment: Recognized a non-cash impairment loss of $6.3 million related to the MitoCareX reporting unit due to a decline in market capitalization and geopolitical risks.
- Financing Expenses: Increased significantly to $8.9 million (from $2.0 million in the prior year) driven by fair value adjustments on warrant liabilities and day-one losses from new PIPE offerings.
- Discontinued Operations: Recorded a gain of $880,000 from the deconsolidation of Save Foods Ltd., offsetting operating losses in that segment.
- Equity Structure: Completed a 1-for-7 reverse stock split in April 2026. Outstanding shares increased to 1,453,333 (post-split) due to recent capital raises.
Guidance, Outlook, and Risks
Capital Raises: The company raised approximately $4.15 million in gross proceeds during June 2026 through two registered direct offerings and concurrent private placements (First and Second PIPE Warrants). These warrants were classified as liabilities, contributing to financing expenses.
Going Concern: Management has expressed substantial doubt regarding the company's ability to continue as a going concern for the next 12 months. The company has an accumulated deficit of $56.3 million and expects to continue generating losses. Future operations depend on securing additional financing.
Key Risks:
- Geopolitical Instability: Ongoing conflict in the Middle East (Israel/Iran/Hezbollah) poses risks to operations, particularly R&D activities located in Israel.
- Regulatory & Development: Uncertainty regarding the commercialization of MitoCareX products and obtaining regulatory approvals.
- Liquidity: Dependence on external equity financing to fund operations and development programs.
Investor Verification Checklist
- Warrant Liability Valuation: Verify the assumptions (volatility, discount rates) used to value the significant warrant liabilities ($13.4 million total), which heavily impact net loss.
- Goodwill Impairment: Review the third-party valuation report supporting the $6.3 million impairment charge for MitoCareX.
- Cash Runway: Assess the sufficiency of the $7.6 million cash balance against projected burn rates for MitoCareX R&D and renewable energy projects.
- Discontinued Operations: Confirm the final settlement terms of the Save Foods Ltd. sale and any remaining contingent liabilities.
- Geopolitical Exposure: Evaluate the specific impact of the Middle East conflict on the timeline and cost of MitoCareX's clinical trials.